4-((3,3-dimethylbutoxy)carbonyloxy)benzyl 2-(4-isobutylphenyl)propanoate | 1224508-75-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-((3,3-dimethylbutoxy)carbonyloxy)benzyl 2-(4-isobutylphenyl)propanoate
• 英文别名: 4-[{2-(4-isobutylphenyl)propanoyloxy}methyl]phenyl 3,3-dimethylbutyl carbonate；[4-(3,3-dimethylbutoxycarbonyloxy)phenyl]methyl 2-[4-(2-methylpropyl)phenyl]propanoate
• CAS: 1224508-75-1
• 化学式: C₂₇H₃₆O₅
• 分子量: 440.58
• InChiKey: LXBFPRSQOWRVRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  527.6±42.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7.6
• 重原子数：
  32
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-((3,3-dimethylbutoxy)carbonyloxy)benzyl 2-(4-isobutylphenyl)propanoate 在 水 作用下， 生成 布洛芬
  参考文献：
  名称：

  [EN] UNIQUE DUAL-ACTION THERAPEUTICS
  [FR] NOUVEAUX PRODUITS THÉRAPEUTIQUES À DOUBLE ACTION

  摘要：

  本文披露了一种新的治疗药物家族，为非甾体抗炎药物提供了一个控制释放途径，其基于酯或酯-碳酸酯骨架。这些药物是乙酰胆碱酯酶的可逆抑制剂，因此对于受益于抗炎和胆碱干预的临床病况是有用的。这些化合物的一般公式如下，其中n = 0, 1；X = C、Si 和 N+；NSAID = 布洛芬、萘普生、消炎宁和双氯芬酸。其他实施方式也被披露。

  公开号：

  WO2010051044A1
• 作为产物：
  描述：

  3,3-dimethylbutyl 4-(hydroxymethyl)phenyl carbonate 、 布洛芬 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以48%的产率得到4-((3,3-dimethylbutoxy)carbonyloxy)benzyl 2-(4-isobutylphenyl)propanoate
  参考文献：
  名称：

  Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction

  摘要：

  The design and study of two classes of noncompetitive acetylcholinesterase inhibitors (AChEIs) which also function as NSAID prodrugs are reported. The most potent AChEIs disclosed contain an aromatic alkyl-aryl linker between an NSAID and a lipophilic choline mimic and they inhibit acetylcholinesterase (AChE) in the submicromolar range. These agents have the therapeutic potential to dually target inflammation by releasing an NSAID in vivo and activating the cholinergic anti-inflammatory pathway via cholinergic up-regulation. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.102

文献信息

• Unique Dual-Action Therapeutics
  申请人：Laskin Jeffrey

  公开号：US20120010168A1

  公开（公告）日：2012-01-12

  A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X═C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.

  本文披露了一种新的治疗药物家族，它提供了一种酯或酯-碳酸骨架的非甾体抗炎药控释输送平台。这些药剂是乙酰胆碱酯酶可逆抑制剂，因此对于受益于炎症抑制和胆碱能干预的临床状况是有用的。这些化合物的一般式为n=0, 1；X=C、Si和N+，NSAID=布洛芬、萘普生、消炎痛和双氯芬酸。还披露了其他实施方式。
• Unique dual-action therapeutics
  申请人：Rutgers, The State University of New Jersey

  公开号：US10570161B2

  公开（公告）日：2020-02-25

  A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X=C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.

  本文公开了一系列新的治疗药物，它们为酯或酯-碳酸酯骨架上的非甾体抗炎药物提供了控释递送平台。这些制剂是乙酰胆碱酯酶的可逆性抑制剂，因此可用于抑制炎症和胆碱能干预的临床病症。这些化合物为通式，其中 n=0、1；X=C、Si 和 N+，NSAID=布洛芬、萘普生、吲哚美辛和双氯芬酸。还公开了其他实施方案。
• UNIQUE DUAL-ACTION THERAPEUTICS
  申请人：Rutgers, The State University of New Jersey

  公开号：US20170143836A1

  公开（公告）日：2017-05-25

  A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n=0, 1; X═C, Si, and N+ and NSAID=ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.
• [EN] UNIQUE DUAL-ACTION THERAPEUTICS<br/>[FR] NOUVEAUX PRODUITS THÉRAPEUTIQUES À DOUBLE ACTION
  申请人：LASKIN JEFFREY

  公开号：WO2010051044A1

  公开（公告）日：2010-05-06

  A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of the general formula wherein n = 0, 1; X = C, Si, and N+ and NSAID = ibuprofen, naproxen, indomethacin and diclofenac. Other embodiments are also disclosed.

  本文披露了一种新的治疗药物家族，为非甾体抗炎药物提供了一个控制释放途径，其基于酯或酯-碳酸酯骨架。这些药物是乙酰胆碱酯酶的可逆抑制剂，因此对于受益于抗炎和胆碱干预的临床病况是有用的。这些化合物的一般公式如下，其中n = 0, 1；X = C、Si 和 N+；NSAID = 布洛芬、萘普生、消炎宁和双氯芬酸。其他实施方式也被披露。
• Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction
  作者：Sherri Young、Karine Fabio、Christophe Guillon、Pramod Mohanta、Timothy A. Halton、Diane E. Heck、Robert A. Flowers、Jeffrey D. Laskin、Ned D. Heindel

  DOI：10.1016/j.bmcl.2010.02.102

  日期：2010.5

  The design and study of two classes of noncompetitive acetylcholinesterase inhibitors (AChEIs) which also function as NSAID prodrugs are reported. The most potent AChEIs disclosed contain an aromatic alkyl-aryl linker between an NSAID and a lipophilic choline mimic and they inhibit acetylcholinesterase (AChE) in the submicromolar range. These agents have the therapeutic potential to dually target inflammation by releasing an NSAID in vivo and activating the cholinergic anti-inflammatory pathway via cholinergic up-regulation. (C) 2010 Elsevier Ltd. All rights reserved.